newsfilter
← Interviews
Y Combinator41 min

Elizabeth Iorns on Biotech Companies in YC

Elizabeth Iorns, Craig Cannon, Elizabeth Lyons

Interview, Fireside Chat

Science Exchange founder and CEO Elizabeth Lyons discusses how Y Combinator accelerates biotech innovation by prioritizing technology de-risking and capital access over traditional market validation. The program addresses the surplus of PhDs entering entrepreneurship by guiding scientists through complex intellectual property licensing and connecting them with Silicon Valley investors seeking deep domain expertise. Current strategic focuses include leveraging AI for drug toxicity prediction, advancing CRISPR applications for genetic editing, and navigating the clinical trial design challenges inherent in longevity research.